Intervention Review

You have free access to this content

Antispasmodics for labour

  1. Anke C Rohwer1,*,
  2. Oswell Khondowe1,
  3. Taryn Young1,2

Editorial Group: Cochrane Pregnancy and Childbirth Group

Published Online: 5 JUN 2013

Assessed as up-to-date: 10 APR 2013

DOI: 10.1002/14651858.CD009243.pub3


How to Cite

Rohwer AC, Khondowe O, Young T. Antispasmodics for labour. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD009243. DOI: 10.1002/14651858.CD009243.pub3.

Author Information

  1. 1

    Stellenbosch University, Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences, Tygerberg, South Africa

  2. 2

    South African Medical Research Council, South African Cochrane Centre, Tygerberg, South Africa

*Anke C Rohwer, Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences, Stellenbosch University, Francie van Zijl Drive, Tygerberg, 7505, South Africa. arohwer@sun.ac.za.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 5 JUN 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram - September 2011 search
[Figure 2]
Figure 2. Study flow diagram - February 2013 search
[Figure 3]
Figure 3. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 4]
Figure 4. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Figure 5]
Figure 5. Funnel plot of comparison: 1 Antispasmodics versus control, outcome: 1.1 Duration of first stage of labour (min).
[Figure 6]
Figure 6. Funnel plot of comparison: 1 Antispasmodics versus control, outcome: 1.6 Rate of NVDs.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Antispasmodics versus control: neurotropic versus musculotropic agents, Outcome 1 Duration of first stage of labour (min).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Antispasmodics versus control: neurotropic versus musculotropic agents, Outcome 2 Duration of second stage of labour (min).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Antispasmodics versus control: neurotropic versus musculotropic agents, Outcome 3 Duration of third stage of labour (min).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Antispasmodics versus control: neurotropic versus musculotropic agents, Outcome 4 Total duration of labour (min).
[Analysis 1.5]
Analysis 1.5. Comparison 1 Antispasmodics versus control: neurotropic versus musculotropic agents, Outcome 5 Rate of cervical dilatation (cm/h).
[Analysis 1.6]
Analysis 1.6. Comparison 1 Antispasmodics versus control: neurotropic versus musculotropic agents, Outcome 6 Rate of normal vertex deliveries.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Antispasmodics versus control: studies including caesarean section versus studies excluding C/S in analysis, Outcome 1 Duration of first stage of labour (min).
[Analysis 2.2]
Analysis 2.2. Comparison 2 Antispasmodics versus control: studies including caesarean section versus studies excluding C/S in analysis, Outcome 2 Duration of second stage of labour (min).
[Analysis 2.3]
Analysis 2.3. Comparison 2 Antispasmodics versus control: studies including caesarean section versus studies excluding C/S in analysis, Outcome 3 Duration of third stage of labour (min).
[Analysis 2.4]
Analysis 2.4. Comparison 2 Antispasmodics versus control: studies including caesarean section versus studies excluding C/S in analysis, Outcome 4 Total duration of labour (min).
[Analysis 2.5]
Analysis 2.5. Comparison 2 Antispasmodics versus control: studies including caesarean section versus studies excluding C/S in analysis, Outcome 5 Rate of cervical dilatation (cm/h).
[Analysis 3.1]
Analysis 3.1. Comparison 3 Antispasmodics versus control: intravenous versus intramuscular versus rectal administration, Outcome 1 Duration of first stage of labour (min).
[Analysis 3.2]
Analysis 3.2. Comparison 3 Antispasmodics versus control: intravenous versus intramuscular versus rectal administration, Outcome 2 Duration of second stage of labour (min).
[Analysis 3.3]
Analysis 3.3. Comparison 3 Antispasmodics versus control: intravenous versus intramuscular versus rectal administration, Outcome 3 Duration of thrid stage of labour (min).
[Analysis 3.4]
Analysis 3.4. Comparison 3 Antispasmodics versus control: intravenous versus intramuscular versus rectal administration, Outcome 4 Total duration of labour (min).
[Analysis 3.5]
Analysis 3.5. Comparison 3 Antispasmodics versus control: intravenous versus intramuscular versus rectal administration, Outcome 5 Rate of cervical dilatation (cm/h).
[Analysis 4.1]
Analysis 4.1. Comparison 4 Antispasmodics versus control: primigravidas versus primi-and multigravidas, Outcome 1 Duration of first stage of labour (min).
[Analysis 4.2]
Analysis 4.2. Comparison 4 Antispasmodics versus control: primigravidas versus primi-and multigravidas, Outcome 2 Duration of second stage of labour (min).
[Analysis 4.3]
Analysis 4.3. Comparison 4 Antispasmodics versus control: primigravidas versus primi-and multigravidas, Outcome 3 Duration of third stage of labour (min).
[Analysis 4.4]
Analysis 4.4. Comparison 4 Antispasmodics versus control: primigravidas versus primi-and multigravidas, Outcome 4 Total duration of labour (min).
[Analysis 4.5]
Analysis 4.5. Comparison 4 Antispasmodics versus control: primigravidas versus primi-and multigravidas, Outcome 5 Rate of cervical dilatation (cm/h).
[Analysis 5.1]
Analysis 5.1. Comparison 5 Antispasmodics versus control: spontaneous versus spontaneous and/or induced labour, Outcome 1 Duration of first stage of labour (min).
[Analysis 5.2]
Analysis 5.2. Comparison 5 Antispasmodics versus control: spontaneous versus spontaneous and/or induced labour, Outcome 2 Duration of second stage of labour (min).
[Analysis 5.3]
Analysis 5.3. Comparison 5 Antispasmodics versus control: spontaneous versus spontaneous and/or induced labour, Outcome 3 Duration of third stage of labour (min).
[Analysis 5.4]
Analysis 5.4. Comparison 5 Antispasmodics versus control: spontaneous versus spontaneous and/or induced labour, Outcome 4 Total duration of labour (min).
[Analysis 5.5]
Analysis 5.5. Comparison 5 Antispasmodics versus control: spontaneous versus spontaneous and/or induced labour, Outcome 5 Rate of cervical dilatation (cm/h).
[Analysis 6.1]
Analysis 6.1. Comparison 6 Antispasmodics versus control: active versus expectant management of labour, Outcome 1 Duration of first stage of labour (min).
[Analysis 6.2]
Analysis 6.2. Comparison 6 Antispasmodics versus control: active versus expectant management of labour, Outcome 2 Duration of second stage of labour (min).
[Analysis 6.3]
Analysis 6.3. Comparison 6 Antispasmodics versus control: active versus expectant management of labour, Outcome 3 Duration of third stage of labour (min).
[Analysis 6.4]
Analysis 6.4. Comparison 6 Antispasmodics versus control: active versus expectant management of labour, Outcome 4 Total duration of labour (min).
[Analysis 6.5]
Analysis 6.5. Comparison 6 Antispasmodics versus control: active versus expectant management of labour, Outcome 5 Rate of cervical dilatation (cm/h).
[Analysis 7.1]
Analysis 7.1. Comparison 7 Antispasmodics versus control: low-risk versus high-risk pregnancies, Outcome 1 Duration of first stage of labour (min).
[Analysis 7.2]
Analysis 7.2. Comparison 7 Antispasmodics versus control: low-risk versus high-risk pregnancies, Outcome 2 Duration of second stage of labour (min).
[Analysis 7.3]
Analysis 7.3. Comparison 7 Antispasmodics versus control: low-risk versus high-risk pregnancies, Outcome 3 Duration of third stage of labour (min).
[Analysis 7.4]
Analysis 7.4. Comparison 7 Antispasmodics versus control: low-risk versus high-risk pregnancies, Outcome 4 Rate of cervical dilatation (cm/h).
[Analysis 8.1]
Analysis 8.1. Comparison 8 Antispasmodics versus control: sensitivity analysis: studies with high risk of bias excluded, Outcome 1 Duration of first stage of labour (min).
[Analysis 8.2]
Analysis 8.2. Comparison 8 Antispasmodics versus control: sensitivity analysis: studies with high risk of bias excluded, Outcome 2 Duration of second stage of labour (min).
[Analysis 8.3]
Analysis 8.3. Comparison 8 Antispasmodics versus control: sensitivity analysis: studies with high risk of bias excluded, Outcome 3 Duration of third stage of labour (min).
[Analysis 8.4]
Analysis 8.4. Comparison 8 Antispasmodics versus control: sensitivity analysis: studies with high risk of bias excluded, Outcome 4 Total duration of labour (min).
[Analysis 8.5]
Analysis 8.5. Comparison 8 Antispasmodics versus control: sensitivity analysis: studies with high risk of bias excluded, Outcome 5 Rate of cervical dilatation (cm/h).
[Analysis 8.6]
Analysis 8.6. Comparison 8 Antispasmodics versus control: sensitivity analysis: studies with high risk of bias excluded, Outcome 6 Rate of normal vertex deliveries.
[Analysis 9.1]
Analysis 9.1. Comparison 9 Antispasmodics versus control: maternal adverse events, Outcome 1 Tachycardia.
[Analysis 9.2]
Analysis 9.2. Comparison 9 Antispasmodics versus control: maternal adverse events, Outcome 2 Mouth dryness.
[Analysis 9.3]
Analysis 9.3. Comparison 9 Antispasmodics versus control: maternal adverse events, Outcome 3 Headache.
[Analysis 9.4]
Analysis 9.4. Comparison 9 Antispasmodics versus control: maternal adverse events, Outcome 4 Nausea.
[Analysis 9.5]
Analysis 9.5. Comparison 9 Antispasmodics versus control: maternal adverse events, Outcome 5 Vomiting.
[Analysis 9.6]
Analysis 9.6. Comparison 9 Antispasmodics versus control: maternal adverse events, Outcome 6 Dizziness.
[Analysis 9.7]
Analysis 9.7. Comparison 9 Antispasmodics versus control: maternal adverse events, Outcome 7 Giddiness.
[Analysis 9.8]
Analysis 9.8. Comparison 9 Antispasmodics versus control: maternal adverse events, Outcome 8 Cervical laceration.
[Analysis 9.9]
Analysis 9.9. Comparison 9 Antispasmodics versus control: maternal adverse events, Outcome 9 Flushing of face.
[Analysis 9.10]
Analysis 9.10. Comparison 9 Antispasmodics versus control: maternal adverse events, Outcome 10 Postpartum haemorrhage.
[Analysis 10.1]
Analysis 10.1. Comparison 10 Antispasmodics versus control: neonatal adverse events, Outcome 1 Admission to NICU.
[Analysis 10.2]
Analysis 10.2. Comparison 10 Antispasmodics versus control: neonatal adverse events, Outcome 2 Fetal distress.
[Analysis 10.3]
Analysis 10.3. Comparison 10 Antispasmodics versus control: neonatal adverse events, Outcome 3 Fetal bradycardia.
[Analysis 10.4]
Analysis 10.4. Comparison 10 Antispasmodics versus control: neonatal adverse events, Outcome 4 Fetal tachycardia.
[Analysis 10.5]
Analysis 10.5. Comparison 10 Antispasmodics versus control: neonatal adverse events, Outcome 5 Meconium-stained liquor.